SYSTEM PROBLEMS:
We are currently experiencing technical problems with content and functionality requiring a login.
We apologize for the inconvience.
Showing session: reset
THE LONG AND THE SHORT OF IT: WHAT'S NEXT FOR LONG-ACTING DRUGS
- Sort by:
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
5 of
5
|
SESSION INTRODUCTION
Ethel D. Weld
The Johns Hopkins University, Baltimore, MD, USA
CABOTEGRAVIR AND RILPIVIRINE PK FOLLOWING LONG-ACTING HIV TREATMENT DISCONTINUATION (ABSTRACT
466)
Susan Ford
GlaxoSmithKline, RTP, NC, USA
MK-8504 AND MK-8583 (TENOFOVIR PRODRUGS) SINGLE-DOSE PK AND ANTIVIRAL ACTIVITY IN HIV INFECTION (ABSTRACT
468)
Randolph P Matthews
Merck Research Laboratories, North Wales, PA, USA
DOSE-RESPONSE RELATIONSHIP OF SUBCUTANEOUS LONG-ACTING HIV CAPSID INHIBITOR GS-6207 (ABSTRACT
469)
Eric Daar
Los Angeles Biomedical Research Institute at Harbor-UCLA Medical Center, Torrance, CA, USA
ANTIRETROVIRAL & RIFAMPICIN COTREATMENT AFFECTS DMPA EXPOSURE: DOSING IMPLICATIONS (ABSTRACT
471)
Jose Francis
University of Cape Town, Cape Town, Western Cape, South Africa
|
<< first | < prev
page:
of 1
|
records per page:
next > | last >>
|
| pages: 1
|
presentations:
1 to
5 of
5
|
